Skip to main content
SpringerLink
Log in
Book cover

Pharmakologie & Toxikologie pp 342–357Cite as

Inhibitoren des Renin-Angiotensin-Aldosteron-Systems (RAAS)

  • Chapter

  • 26k Accesses

Part of the book series: Springer-Lehrbuch ((SLB))

Zusammenfassung

Das Renin-Angiotensin-Aldosteron-System (RAAS ) ist ein zentraler Steuerungsmechanismus, mit dem der Organismus seinen Elektrolythaushalt reguliert und einen ausreichenden Füllungszustand des Gefäßsystems sowie einen ausreichenden Blutdruck sicherstellt. Das RAAS ist in die Pathophysiologie verschiedener Erkrankungen wie der arteriellen Hypertonie, der chronischen Herzinsuffizienz oder der diabetischen Nephropathie involviert.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Weiterführende Literatur

  • Bader M (2010) Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy. Annu Rev Pharmacol Toxicol 50: 439–465

    Article  PubMed  CAS  Google Scholar 

  • Farese RV, Biglieri EG, Shackleton CHL, Irony I, Gomez-Fontes R (1991) Licorice-induced hypermineralocorticoidism. N Engl J Med 325:1223–1227

    Article  PubMed  Google Scholar 

  • Goldstein S (2002) Benefits of β-blocker therapy for heart failure. Arch Intern Med 162: 641–648

    Article  PubMed  CAS  Google Scholar 

  • Gradman AH, Kad R (2008) Renin inhibition in hypertension. J Am Coll Cardiol 51: 519–528

    Article  PubMed  CAS  Google Scholar 

  • Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543–551

    Article  PubMed  CAS  Google Scholar 

  • McMurray JJV (2010) Systolic Heart Failure. N Engl J Med 362: 228–238

    Article  PubMed  CAS  Google Scholar 

  • Pitt B, Zaninad F, Rmme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) For the Randomized Aldactone Evaluation Study (RALES ) Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709–717

    Article  PubMed  CAS  Google Scholar 

  • Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289: 871–878

    Article  PubMed  CAS  Google Scholar 

  • Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW (2007) Reninangiotensin system and cardiovascular risk. Lancet 269: 1208–1219

    Article  Google Scholar 

Download references

Authors
  1. S. Offermanns
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Offermanns, S. (2012). Inhibitoren des Renin-Angiotensin-Aldosteron-Systems (RAAS). In: Pharmakologie & Toxikologie. Springer-Lehrbuch. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12354-2_37

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12354-2_37

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12353-5

  • Online ISBN: 978-3-642-12354-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation